• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jerome Ritz, MD

Professor, Department of Medicine, Harvard Medical School

Executive Director, Connell O'Reilly Cell Manipulation and Gene Transfer Laboratory, Dana-Farber Cancer Institute

Professor of Medicine, Medicine, Dana-Farber Cancer Institute

Contact Info

Jerome Ritz
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Mayer 530
Phone: 617-632-3465
Fax: 617-632-5167


Ryley Conlon
Administrative Specialist
Dana-Farber Cancer Institute
450 Brookline Ave. Mayer 530
Boston, MA, 02115
Phone: 617-582-8461

DF/HCC Program Affiliation

Cancer Immunology

DF/HCC Associations

Member, Clinical Science Coordinating Committee
Associate Director, Core Facilities, Executive Committee
Member, Center Scientific Council
Executive Director, Cell Manipulation

Research Abstract

Hematopoietic stem cell transplantation provides effective therapy for patients with a variety of hematologic malignancies, but this continues to be a very intensive and potentially dangerous treatment approach. With recent improvements in supportive care, the most common causes of treatment failure are disease relapse and infectious complications associated with immune deficiency following transplant. To address these 2 issues, my laboratory research is focused on the characterization of immune reconstitution following allogeneic hematopoietic stem cell transplantation. It is now well established that reconstitution of donor hematopoiesis not only replaces the recipients own immune system but also results in the development of immunity against patient tumor cells. This development of anti-tumor immunity is very effective and plays an important role in the prevention of relapse following stem cell transplantation. Both laboratory projects and clinical trials are attempting to define the immunologic mechanisms as well as the target antigens of this response. With better understanding of the mechanisms and target specificity of the graft-versus-leukemia (GVL) response, it will be possible to distinguish GVL from graft-versus-host disease (GVHD) and to develop new methods for selectively enhancing GVL.


View All Publications